Literature DB >> 6238120

Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

M E Medof, T Kinoshita, V Nussenzweig.   

Abstract

Decay-accelerating factor (DAF), extracted from the stroma of human erythrocytes, was purified to homogeneity and incorporated into the membrane of sheep red cell complement intermediates, where its functional properties were analyzed. Incorporation of DAF into the cell membranes was temperature dependent, took place on pronase- or trypsin-treated erythrocytes, and did not depend on prior deposition of antibody, C1 or C4. Serum lipoproteins (high and low density) effectively inhibited DAF incorporation, but had no effect on the activity of DAF after its association with the cell membrane. The incorporated DAF could not be removed from the red cell surface by repeated washings in the presence of high salt concentration but was solubilized when the stroma were extracted with 0.1% Nonidet P-40. The presence of DAF in the membrane of EA did not affect the deposition of C1 and C4, but as few as 10(2) DAF molecules per cell profoundly inhibited the assembly of C3 and C5 convertases of both the classical and alternative pathways. The DAF inhibitory effect on EAC14 or EAC43 was not overcome by supplying an excess of C2 or factor B, but the alternative pathway C3 convertase could be assembled in the presence of Ni++, or nonphysiological concentrations of Mg++, which enhances the binding affinity of factor B for C3b. The DAF effect on EAC14 or EAC143 was entirely reversed by treating the cells with specific anti-DAF antibodies, showing that DAF did not alter the structure of C4b or C3b. Taken together, the experimental evidence suggests that DAF interacts directly with membrane-bound C3b or C4b and prevents subsequent uptake of C2 and factor B. DAF can function only within the cell membrane. Indeed, the decay dissociation of the C4b2a enzyme on DAF-containing sheep intermediates was not changed by varying the cell concentration. DAF-treated EA had no influence on the decay of nontreated EAC142 present in the same mixture. Moreover, the inhibitory activity of intact human erythrocytes on C4b2a was not blocked by antibodies to DAF, but was abolished by antibodies to the C3b/C4b receptor (CR1). When incorporated into the membrane of rabbit erythrocytes, human DAF inhibited their lysis by human complement. In conclusion, on the basis of these and previous results, it appears that DAF plays a central role in preventing the amplification of the complement cascade on host cell surfaces.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238120      PMCID: PMC2187498          DOI: 10.1084/jem.160.5.1558

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

1.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

2.  Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

6.  The reaction mechanism of human C5 in immune hemolysis.

Authors:  N R Cooper; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

7.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

8.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

9.  Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Properdin factor D: characterization of its active site and isolation of the precursor form.

Authors:  D T Fearon; K F Austen; S Ruddy
Journal:  J Exp Med       Date:  1974-02-01       Impact factor: 14.307

View more
  199 in total

1.  Inside the mouse hospital: science, animal welfare and strife in the drive for AAALAC accreditation.

Authors:  V Hampshire; J Davis
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

Review 2.  Stem cell transplantation for paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Haematologica       Date:  2010-06       Impact factor: 9.941

3.  Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.

Authors:  C Hale; M Bartholomew; V Taylor; J Stables; P Topley; J Tite
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 4.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

5.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

6.  Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Authors:  Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

7.  Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80).

Authors:  R S McHugh; S N Ahmed; Y C Wang; K W Sell; P Selvaraj
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

8.  Tissue distribution of the guinea-pig decay-accelerating factor.

Authors:  K Nishikawa; S Matsuo; H Tamai; N Okada; H Okada
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

9.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Authors:  Peter N Lalli; Michael G Strainic; Min Yang; Feng Lin; M Edward Medof; Peter S Heeger
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.